Index

AAV2-neurturin, 273, 276
acamprosate, 17
acceptability, rating scales, 232
accordion-pill carbidopa-levodopa, 86
acetylcholine deficiency, 141
activities of daily living (ADLs), 122, 199, 351
acupuncture, 353
acute anticholinergic syndrome, 10
ADAGIO study, 26, 30, 269, 272, 274, 275, 328
ADAS-cog scale, 325, 326, 332
ADCS-CGIC scale, 325, 332
adenosine A2a antagonists, 86
  istradefylline, 86–87
  preladenant, 87
  tozadenant, 87–88
ADS-5102, 89
advanced stage PD
  COMT inhibitors, 78, 80
  DBS, 313–16
  levodopa treatment summary, 72–73
adverse effects
  anticholinergics, 9–10
  apomorphine, 57
  bilateral pallidal DBS, 304
  bilateral pallidotomy, 303
  DBS, 314, 317
  donepezil, 326
  dopamine agonists, 41–43
  intranasal apomorphine, 53
  rasagiline, 27
  rivastigmine, 326
  rotigotine transdermal system, 52
  selegiline, 27
  STN DBS, 198, 199–202, 306
  subthalamotomy, 305
  surgery, 308
  thalamotomy vs thalamic DBS, 299
  tolcapone, 79
  VIM DBS, 211, 212
AE program, 285
aerobic exercise, 349–50
AFQ056, 89–90
agoraphobia, 130
AIMS scale, 233
akathisia, 165, 166
akinetic crisis, 16
akinetic rigid syndromes, 2
ALDS scale, 304, 307
alertness, 151, 218
alpha-blockers, 103
alpha-synuclein, 253–54, 268
Alzheimer's disease, 76, 111, 117, 125, 128, 141
  beta-amyloid and tau proteins, 255
AM IMPAKT study, 56
amantadine, 13–20, 101
  ADS-5102, 89
  compulsive behaviour treatment, 17
  dyskinesias treatment, 14
  ICDs, 329
  levodopa and, 69
amitriptyline, 101
amnestic multiple-domain MCI, 122
amnestic single-domain MCI, 111, 122
amphetamine, 135
amyloid, beta, 255, 268
analgesics, 165, 167
anger, 291
animal models, 270–71
  dopaminergic neuroprotection, 318
  exercise, 350
  lack of, 266
  toxin-induced, 271
  transgenic, 271
antibodies measures, 257
anticholinergics, 5–10, 132
  adverse effects and contraindications, 9–10
  current use in PD management, 7–9
  future use, 10
  levodopa synergy, 9
  pharmacokinetics and pharmacodynamics, 6–7
  psychosis effects, 141
  sialorrhea, 101
  urinary dysfunction, 102
antidepressants, 27, 104, 112, 130, 133, 167
  tricyclic, 103, 133, 327
antidyskinetics, 89–90
antiglutamatergics, 13–20
  akinetic crisis and neuroleptic malignant syndrome, 16
  cognitive improvement, 16
  dyskinesia studies, 16
  evidence-based results and meta analyses, 14–16
  four main effects, 18
  ICD and other compulsive disorders, 17–18
  psychosis induction, 17
antihypertensives, 104
antimuscarinics, 5
antipsychotics, 132, 141
anxiety, 128, 129–31, 330
  categories, 130
apathy, 128–29, 330
  DBS and, 147
  definitions, 128
  depression and dementia, 129
  syndrome, 129
  treatment, 129
apomorphine, 53–54, 80, 155
  adverse effects, 57
  ICDs, 57
  intranasal, 53
  long-term therapy effects, 57
  motor effects, 54–56
  non-motor effects, 56–57
  pain relief, 166
  pharmacokinetics, 54
  sexual dysfunction, 104
  subcutaneous, 100
  transdermal patch, 52
aripiprazole, 132, 329
art therapy, 356
aspiration pneumonia, 340
ataxia, limb, 183
atomoxetine, 124, 326
atropine, 5, 101
attention deficit disorder, 326
attention training, 113
atypical parkinsonism, 66, 196, 243, 281
auditory cues, 354
auditory hallucinations, 131
autonomic dysfunction, 93. *See also* constipation; gastroparesis; orthostatic hypotension; sialorrhea
  defecatory, 100
  drug treatment, 95
  sexual, 104–6
  thermoregulatory, 106
  urinary, 102–4
axial symptoms, anticholinergic effects on, 8

back pain, 166
bapineuzemab, 255
Barthel index, 300
Beck Depression Inventory (BDI), 291
behavioral disturbances, 127. *See also* depression; fatigue; impulse control disorders (ICD); psychosis
  anxiety, 128, 129–31, 330
  apathy, 128–29, 330
  deep brain stimulation and, 146–48
  drug treatment, 148
  personality, 128
  treatment-related, 139–40

© in this web service Cambridge University Press www.cambridge.org

Index

behavioral treatment, urinary dysfunction, 102, 343
benign prostatic hypertrophy, 103
benign tremulous parkinsonism, 213
benserazide, 23, 67, 76
benzodiazepines, 130
benztropine, 7
beta-amyloid, 255, 268
bilateral GPi DBS, 303–4
bilateral pallidotomy, 302
bilateral posteroventral pallidotomy, 302
bilateral subthalamic DBS, 306–8
bilateral subthalamotomy, 306
bilateral thalamotomy, 179, 299, 300
biofeedback, 100
BioFIND study, 251
biomarkers, 268
  CSF and blood, 250–53
  definition, 249
  dopamine-based, 253–58
  future directions, 259–60
  ideal characteristics for PD, 251
  in clinical trials, 250
  metabolomics, 259
  neuroimaging, 250, 267
  neuroprotective trials, 266, 268
  proteomics, 259
  transcriptomics, 258–59
biperiden, 7
bisacodyl, 99
blood biomarkers, 250–53
  dopamine-based, 253–58
Botox, 100, 103, 338
botulinum toxin, 93, 95, 98, 100, 101, 103
botulinum toxin type A, 337–39
  urinary dysfunction, 342
botulinum toxin type B, 339
bradykinesia, 2, 289
brain function, measurement in trials, 246
brain network imaging, 243
bromocriptine, 34, 35
bupropion, 133, 327

cabergoline, 35, 37, 155, 156
caffeine, 157, 345
calcium channel antagonists, 90
CALM-PD study, 38, 244, 250, 267, 272, 275
CAPIT protocol, 195
CAPSIT protocol, 177, 195–96, 197
car accidents, 41, 152, 154
carbidopa, 23, 67, 68, 69, 70, 76
  accordion pill, 86
  intestinal gel, 70–71, 83–84
cardiac pacing, 97
Carlsson, Arvid, 1
carpal tunnel syndrome, 166
catechol-o-methyl transferase (COMT) inhibitors, 67–68, 76–81
catheterization, 103
CATIE-AD trial, 333
caudal Zona incerta (cZi), 218
central fatigue, 134
central pain, 165, 167
centremedian-parafascicular complex (CM-Pf), 221
CEP-1347, 273, 276
cerebellothalamic tract, 219
cerebrospinal fluid (CSF) biomarkers, 250–53
  dopamine-based, 253–58
CGI scale, 344
Charcot, Professor, 5
Charles Bonnet's syndrome, 141
chewing gum, 101
cholinergic system, 5–6
cholinesterase inhibitors, 112, 123–24, 129, 132, 141
CIBIC scale, 326
cisapride, 98, 99
CISI-PD scale, 233
citalopram, 328
classical test theory (CTT), 231
CLEOPATRA-PD study, 40
clinical trials. *See also* neuroprotective trials
  biomarkers in, 250
  design, 270–71
  early stage PD, 280–85
  functional imaging markers in, 244–46
  NPS, 330–33
clinician-based rating scales, 232–34
clonazepam, 156
closed-loop devices, 224
clozapine, 132, 141, 329
Cochrane review
  anticholinergics, 8
  monoamine oxidase inhibitors, 25
coenzyme Q10, 256, 273, 277
cog wheeling, 3
cognitive behavioral therapy (CBT), 134, 328
cognitive impairment, 293. *See also* mild cognitive impairment (MCI)
  background, 111–12
  drug treatment, 112, 123–24, 124
  epidemiology, 122
  exercise and, 350
  future directions, 118
  GPi DBS, 191
  GPi vs STN DBS, 290
  neuropsychological profile and bedside assessment, 122–23
  non-drug interventions, 116–18, 125
cognitive improvement, 16, 352
cognitive rehabilitation, 113, 116–17
cognitive stimulation, 114, 117
colchicine, 100
COMPARE study, 342
COMPASS-OD scale, 344
compensatory rehabilitation, 112, 117
composite endpoints, 332
compulsive disorders, 17–18
COMT inhibitors. *See* catechol-o-methyl transferase (COMT) inhibitors
consistency, rating scales, 232
constant voltage stimulator, 225
constipation, 98–100, 341–42
  drug treatment, 95
continuous drug delivery (CDD), 48
controlled release levodopa, 67
Cotzias, George, 1
cranial electrotherapy stimulation (CES), 168
creatine, 272, 276
creative arts therapies, 353–57
CSP 468 study, 190
CVT-301, 86
cyclic GMP phosphodiesterase type 5 inhibitors, 105
cystometric analysis, 342

DAICE-ET survey, 52
Dai-Kenchu-To (DKT), 100
dance therapy, 355–56
darifenacin, 103
DAT scans, 267, 281
DATATOP study, 24, 27, 90, 251, 254, 255, 271, 272
DAWS (DAg withdrawal syndrome), 43, 144–45
daytime sleep disorders, 41, 152–53, 345–46
deep brain stimulation (DBS), 83, 118, 146–48, 157–58. *See also* globus pallidus internus (GPi) DBS; subthalamic nucleus (STN) DBS; ventral intermediate nucleus (VIM) DBS
  advanced stage PD, 313–16
  advantages and drawbacks, 298
  alternative targets, 202
  awake/asleep, 292
  centremedian-parafascicular complex, 221
  development, 176
  early stage PD, 282–83, 320–22
  hemorrhage risk, 182
  introduction, 297
  mid stage PD, 316–20
  novel stimulation paradigms and devices, 224–25
  nucleus basalis of Meynert, 221–22
  other targets, 216
  pain relief, 162, 166, 167
  pedunculopontine nucleus, 216–18, 218
  posterior subthalamic area, 218–19
  post-operative surveillance, 147
  substantia nigra, 219–21
  vs. surgery controversy, 308–9
  thalamic, 298–300
defecatory dysfunction, 100
delayed-start design, 265, 269–70, 274
delirium, 141
delusions, 131, 135, 140
dementia, 111, 112, 122, 128, 135, 325–27. *See also* Alzheimer's disease
  DBS and, 196
  depression and apathy, 129
  with Lewy bodies, 128, 131
  NBM DBS and, 222
  psychosis and, 131
Denny-Brown, Derek, 1
depression, 132–34, 327–28
  anxiety and, 130
  apathy and dementia, 129
  categories, 128
  DBS and, 147, 196
  fatigue and, 127
  GPi vs STN DBS, 291
  pain and, 164, 167

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-05386-1 — Parkinson's Disease
Edited by Néstor Gálvez-Jiménez , Hubert H. Fernandez , Alberto J. Espay , Susan H. Fox
Index
More Information

pramipexole effects on, 39
treatment, 133–34
desmopressin, 97, 103
despiramine, 328
detrusor areflexia, 103
dextromethorphan, 16
DFSS scale, 339
Diagnostic and Statistical Manual (DSM) IV TR, 127, 128, 130, 132, 332
Diagnostic and Statistical Manual (DSM) V TR, 142
diet, 97
high-fiber, 98
disease modification, 265
disease-modifying treatments, 90
DJ-1 gene, 254
DM-1992, 86
docusate, 99
domperidone, 54, 57, 93, 95, 96, 97, 344
donepezil, 123, 124, 331
cognitive impairment, 112, 113, 326
DOPA decarboxylases, inhibitors, 63, 66
dopamine
based biomarkers, 253–58
compulsive misuse, 147
dopamine agonist withdrawal syndrome (DAWS), 43, 144–45
dopamine agonists, 34–35
adverse effects, 41–43
continuous drug delivery, 48
early stage PD, 283–85
ICDs and, 142, 143
intranasal, 53
levodopa and, 69
major clinical trials, 275
most common daily usage, 37–41
pharmacodynamics, 36–37
pharmacokinetics, 37
rationale for use in PD, 35–36
sexual dysfunction, 104
subcutaneous, 53–58
transdermal, 48–53, 58
dopamine dysregulation syndrome, 66, 142, 143–44
dopamine receptors, classes, 36
dopamine system
functional imaging, 242–44
integrity, 245
dopaminergic areas of the brain, 153
dopaminergic neuroimaging, 266–67
dopaminergic neuroprotection, 319
doxepin, 156
drooling, 100. *See also* sialorrhea
droxidopa, 94, 95, 96
duloxetine, 167, 344
duodenal delivery methods, 70
dysarthria, 211
dysautonomia scale, 236
dyskinesias. *See also* motor symptoms
amantadine effects on, 14
antidyskinetics, 89–90
antiglutamatergic studies, 16
DBS, 190
development in PD, 13
GPi vs STN DBS, 289
levodopa-induced, 13, 65, 89, 289
pallidotomy effect on, 179
rating scales, 233
STN DBS and, 199
thalamotomy effect on, 178
dysphagia, 340–41
Dysport, 101, 104, 337, 342
dystonia
anticholinergic effects on, 8
pain related to, 165–66

early stage PD
clinical trials, 280–85
DBS, 282–83, 320–22
definition, 280
exercise, 285
medications, 283–85
MRI scanning, 281
nuclear imaging, 281–82
severity and onset of symptoms, 280
somatostatin levels, 282
treatment summary, 72
vitamin D deficiency, 282
EARLYSTIM trial, 196
economic impact, 315, 318
edemas, pedal and peripheral, 42
effect size (ES), 231
EFNS classification, 23, 28, 30
elderly
anticholinergic adverse effects, 9
summary of treatments in early stage PD, 72
electrical stimulation, 342
cranial electrotherapy, 168
gastric, 98
surface therapy, 341
tDCS, 118
electroconvulsive therapy (ECT), 133, 135, 224
ELLDOPA study, 65, 134, 250, 267, 272, 274
emotional incontinence, 135
EMST device, 340
entacapone, 67, 68, 77, 78–79
epidural spinal cord stimulation (eSCS), 222–24
Epworth sleepiness scale, 153, 154, 345
EQ-5D scale, 237
erectile dysfunction, 104–5, 343
drug treatment, 95
erythromycin, 98
erythropoietin, 97
eszopiclone, 155, 346
excessive daytime sleepiness (EDS), 152, 157, 345
excitotoxicity, 123
executive dysfunction, 111, 122
exercise. *See* physical exercise
external cues, 354

fatigue, 134–35
depression and, 127
scales, 236
Fatigue Assessment inventory, 134
FBF program, 285
FD-PET, 266
feasibility, rating scales, 232
fiberoptic endoscopy, 340
fibrosis, 69
FILOMEN study, 78
fipamezole, 89
Fitness Counts program, 285
fludrocortisone, 94, 95, 344
fluorodopa PET (Fdopa PET), 316
fMRI scanning, 243
forced aerobic exercise, 350
freezing of gait, 221
scale (FOGQ), 235
Frenchay Activities Index, 179, 299
FSS scale, 236
functional imaging, 242
dopamine system integrity, 242–44
functional imaging markers, 244
in clinical trials, 244–46
outcome measures development, 246–47
futility studies, 270

gait abnormalities, 3, 221, 289
gait improvement, 351, 354
gait training, 350, 354
galantamine, 123, 124
gambling, pathological, 142
gastric electrical stimulation, 98
gastrointestinal symptoms scale, 236
gastroparesis, 56, 97–98
drug treatment, 95
gel electrophoresis, 2D, 259
generalized anxiety, 130
Global Biomarkers Standardization Consortium (GBSC), 260
globus pallidus externus (GPE), 288
globus pallidus internus (GPi) DBS, 146, 147, 187, 287
anatomy and physiology, 287–88
background, 287
bilateral, 303–4
complications, 190–92
mechanism, 187–88
medication reduction, 292
motor symptoms, 289–90
neuroimaging, 292
non-motor symptoms, 290–91
operation risks, 293
outcomes, 189
patient selection, 188
programming challenges following, 292
stimulation, 288
vs. STN DBS, 190, 192, 294
technique, 188–89
unilateral, 301–2
glucose metabolism, 267
glutamate receptors, 15, 16
glutamatergic neurotransmission, 13, 14
glutathione, 256
glycopyrrolate, 93, 95, 101, 340
group singing, 354

hallucinations, 131, 140, 141
auditory, 131
minor, 140
presence and passage, 131
visual, 131, 141
HDRS-17 scores, 327
health-related quality of life scales, 236–37, 238

© in this web service Cambridge University Press www.cambridge.org

Index

hedonistic homeostatic dysregulation, 144
hemiballism, 182, 183
hemorrhage, 182, 293
  intracranial, 201
hepatotoxicity, 79
Hoehn and Yahr staging (HY), 4, 232, 280
homovanillic acid (HVA), 253
Hopkins verbal learning test, 290
5HT2A, 141
5HT4 agonists, 99
Human Plasma Proteome Project (HPPP), 260
hypersexuality, 104, 142
hypomania, 142, 147
hypotension. *See also* orthostatic hypotension
  postural, 42, 105

illusions, 140
immunotherapy, 254
impulse control disorders (ICD), 13, 17–18, 329
  apomorphine and, 57
  characterization, 142
  dopamine agonists, 35, 42
  rotigotine role in, 52
  scales, 236
  treatment related, 142–43
incontinence
  urge incontinence, 102
  urinary, 343
indomethacin, 97, 343
inflammation markers, 256–58
infusion levodopa therapy, 70–72
inosine, 90, 256, 257
insomnia, 151, 155–56
interpretability, in rating scales, 231
intranasal dopamine agonists, 53
ionotropic glutamates, 15, 16
ipratropium bromide, 101, 339
IPX066, 69, 84–85
ischemic stroke, 201
isradipine, 90, 284
istradefylline, 86–87
item response theory (IRT), 231
iTRAQ analysis, 259

Lactobacillus casei Shirota, 99
lactulose, 99
L-amino acid decarboxylase (L-AAD), 76, 81
LARGO study, 26, 80
latent trait theories (LTT), 231
lateral pain system, 162
laxatives, 99
lazabemide, 25
L-deprenyl. *See* selegiline
LEAPS study, 275
lesioning, 178. *See also* surgery
  size of lesion, 308
levodopa, 63, 76. *See also* carbidopa
  advanced-stage PD treatment summary, 72–73
  amantadine and, 69
  anticholinergic synergy, 9
  COMT inhibitors and, 67–68
  controlled release, 67
  dopamine agonists and, 69
  early-stage PD treatment summary, 72
  history of PD therapy, 63–64
  infusion therapy, 70–72
  insomnia and, 155
  major trials, 272, 274–75
  monoamine oxidase inhibitors and, 68
  motor complications, 34, 35, 65
  non-motor complications, 65–66
  novel approaches to delivery, 83–86
  novel formulations, 69–70
  pain management, 344
  peripheral neuropathy and, 168, 169
  pharmacokinetics and pharmacodynamics, 64–65, 67, 68
  radiolabeled, 242
  rasagiline adjunct therapy, 25–26
  sleep disorders and, 156
  standard oral therapy, 66–67
levodopa induced dyskinesias (LIDs), 13, 65, 89, 289
levodopa test, 67
Levodopa-Carbidopa Intestinal Gel (LCIG), 70–71, 83–84
Lewy bodies, 253
  dementia with, 128, 131
Lewy, Freidrich, 1
limb ataxia, 183
liquid paraffin, 99
lisuride, 52, 58
local field potential (LFP) recording, 177
long-duration response, 64
lubiprostone, 93, 100, 342

macroelectrode mapping, 177, 188, 189, 198
macrogol, 93, 99, 341
magnetic stimulation, 100
MALDI-TOF MS, 259
malondialdehyde, 256
mania, 142, 147
MAO inhibitors. *See* monoamine oxidase inhibitors
massage therapy, 353
Mattis Dementia Scale, 290
MCI. *See* mild cognitive impairment (MCI)
MDS-UPDRS, 233, 266
  M-EDL, 235
  nM-EDL, 235
medial pain system, 162
M-EDL scale, 235
melatonin, 155, 156, 346
memantine, 16, 17, 123, 346
  clinical trial, 331
  cognitive impairment, 113, 326
memory performance, 111
messenger RNAs (mRNAs), 258
metabolomics, 259
metabotropic glutamates, 15, 16
methylphenidate, 135, 157
metoclopramide, 98
MFI scale, 236
microelectrode mapping, 177, 188, 189, 198
microelectrode recording (MER), 287, 288, 292
microglial activation, 256
mid stage PD, DBS, 316–20
midodrine, 94, 95, 96
mild cognitive impairment (MC)
  types, 122
mild cognitive impairment (MCI), 111, 122, 325–27. *See also* cognitive impairment
  types, 111
minimally important change (MIC), 231, 232
minimally important difference (MID), 232, 233
minocycline, 272, 276
minor hallucinations, 140
mirabegron, 103
mirtazepine, 133
MitoQ study, 273
mitoquinone, 273
modafinil, 135, 157, 345
monoamine oxidase inhibitors, 23. *See also* rasigiline; selegiline
  background, 23
  COMT inhibitors and, 81
  future role, 28
  levodopa and, 68
  major trials, 271–74
  serotonin syndrome, 27–28
MONOCOMB study, 25
Montreal Cognitive Assessment (MoCA), 123
mosapride, 98, 99
motor changing rate (MCR), 52
motor complications and dyskinesia scales, 233
motor cortex stimulation (MCS), 222
motor impairment and disability scales, 233
motor symptoms. *See also* dyskinesias
  apomorphine effects on, 54–56
  drug treatment, 124
  GPi DBS vs. STN DBS, 289–90
  levodopa and, 34, 35, 65
  post-surgery, 183
  prevention of, 35
  rating scales, 233, 235
  ropinorole and, 39
  rotigotine and, 40, 50
  Tai-Chi and, 352
movement disorders
  categories, 2
  first recognition, 1
  improving, 353
Movement Disorders Society (MDS)
  definitions, 23, 29
  guidelines, 30
MPTP model, 271
MRI scanning, 243, 281
  fMRI, 243
multidomain scales, 233, 238
multimodal imaging, 244, 247
multiple domain MCI, 111, 122
multiple-system atrophy (MSA), 282, 343
muscle strength, loss of, 351
musculoskeletal pain, 164, 165
music therapy, 353–55

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-05386-1 — Parkinson's Disease
Edited by Néstor Gálvez-Jiménez , Hubert H. Fernandez , Alberto J. Espay , Susan H. Fox
Index
More Information

naltrexone, 330
ND0611, 70
nebicapone, 77, 80
Neria line, 54, 57
NET-PD LS-1 study, 272
NET-PD study, 272, 275
neural stimulation, 115, 118
neurodegeneration, measurement in trials, 245
neuroimaging. *See also* PET scanning
  biomarkers, 250, 267
  dopaminergic, 266–67
  GPi DBS vs STN DBS, 292
  neuroinflammation, 243
neuroleptic malignant syndrome, 16
neuroleptics, 112
neuromodulation, 104
neuromuscular complications, 168–69
neuropathic pain, 164, 165, 166
neuroprotection, 265, 316, 320
  dopaminergic, 319
neuroprotective trials. *See also* clinical trials
  animal models, 270–71
  biomarkers, 266, 268
  clinical measures, 266
  dopaminergic neuroimaging, 266–67
  future directions, 277
  glucose metabolism, 267
  limitations, 265–66
  results from major studies, 271, 272, 273, 271–77
  structural imaging, 268
neuropsychiatric symptoms (NPS), 325. *See also* non-motor symptoms
  clinical trials, 330–33
  scales, 235
neuropsychological tests, 116
neurturin, 273, 276
neutrophin-3, 100
NHP scale, 237
NICE guidelines, 25, 35
nighttime sleep disorders, 151–52
NMDA receptor antagonists, 112
NMDA receptors, 123
nM-EDL, 235
NMS Questionnaire, 235
nociceptive pain, 164
nocturia, 102
NOMESAFE study, 78
non-amnestic multiple-domain MCI, 122
non-amnestic single-domain MCI, 111, 122
non-invasive brain stimulation, 224
non-motor off symptoms, 127, 130
non-motor symptoms, 337. *See also* autonomic dysfunction; behavioral disturbances; cognitive impairment; neuropsychiatric symptoms (NPS); sleep disorders
  apomorphine and, 56–57
  GPi vs STN DBS, 290–91
  levodopa, 65–66
  post-surgery, 183
  rating scales, 238
  ropinirole and, 39
  rotigotine and, 40
  rotigotine RTS and, 51
  scales, 234, 235–36
  therapeutic approach, 338
Non-Motor Symptoms Scale (NMSS), 40, 51, 55, 234
nortriptyline, 327
NPS. *See* neuropsychiatric symptoms (NPS)
NSAIDs, 165
nuclear imaging, 281–82
nucleus basalis of Meynert (NBM), 221–22

obstructive sleep apnoea (OSA), 152, 157
octreotide, 97
off phase, 65, 166, 179, 195
6-OHDA model, 271, 319, 350
olanzapine, 132, 329
on phase, 65
opicapone, 68, 77, 80
optic tract, 188
orthostatic hypotension, 42, 93–94, 343–44
  definition, 93
  drug treatment, 95, 94–97
  drugs causing, 94
  non-pharmacological management, 94
  symptoms, 93
osmotic laxatives, 99
outcome measures. *See also* clinical trials; rating scales
  functional imaging markers, challenges, 245–46
  functional imaging markers, development, 246–47
oxidative stress, markers, 255–56
oxybutynin, 102

pain, 162–68, 169–70, 344–45
  classification and treatment, 164, 165
  epidural spinal cord stimulation, 222
  non-pharmacologic management, 167
  risk factors in PD, 164
pallidal DBS. *See* globus pallidus internus (GPi) DBS
pallidothalamic tract, 219
pallidotomy, 167, 187, 297. *See also* surgery
  bilateral, 302
  introduction, 175
  outcomes, 179–81, 182
  pain and, 162
  posteroventral, 297, 301, 302
  revitalization, 176
  target confirmation, 177
  unilateral, 300–301
panic attacks, 130
parallel group studies, 268
paranoid delusions, 131
pardoprunox, 284
paresthesias, 211
Parkinson, James, 1, 162
Parkinson's Progression Markers Initiative (PPMI), 251
Parkinson's disease. *See also* advanced stage PD; early stage PD
  atypical, 66, 196, 243, 281
  behavioral effects of treatment, 139–40, 148
  benign tremulous, 213
  cholinergic system and, 5–6
  clinical diagnosis, 63
  experimental pharmacological treatment, 83–91
  first recognition, 1
  mid stage PD, 316–20
  pathological changes, 4
  stages, 3
  summary of treatments for advanced stage, 72–73
  summary of treatments for early stage, 72
  symptoms, 2–3
  UK Brain Bank Criteria, 281
paroxetine, 133, 327
passage hallucinations, 131
patient-reported outcomes (PRO), 231, 234–36
PD Sleep Scale, 154
PDQ-39, 84, 199, 237, 301, 307
PDQ-8, 237
PDQL scale, 237
PDSS scale, 236
PDSS-2 scale, 41, 236
PDYS-26 scale, 235
peak V02, 349
pedal edema, 42
pedunculopontine nucleus (PPN), 6, 216–18, 218
pelvic floor muscle exercises, 102
Penetration-Aspiration scale, 340
percutaneous endoscopic gastrostomy (PEG), 70
pergolide, 35, 37, 104, 155
periodic limb movement disorder (PLMD), 152
periodic limb movements of sleep (PLMS), 156
peripheral edema, 42
peripheral neuropathy, 166, 168–69
personality, 128
PET scanning, 242, 243, 246, 250
  Fdopa PET, 316
  FD-PET, 266
  REAL-PET study, 244, 250, 267, 272, 275
PFS-16 scale, 236
phencyclidine, 14
physical exercise, 114, 117–18, 165, 167, 349
  aerobic, 349–50
  dance, 355–56
  early stage PD, 285
  resistance training, 351–52
  Tai-Chi, 352–53
physiological fatigue, 134
pimavanserin, 132, 142, 329
PIMS scale, 237
pimvanserin, 331
piribedil, 35, 36, 37, 41
  mechanism of action, 41
  motor systems efficacy, 41
  non-motor systems efficacy, 41
  transdermal patch, 52
Pittsburgh Sleep Quality Index, 154
placebo response, 330
pneumonia, aspiration, 340
polyethylene glycol (PEG) 3350, 99
polysomnography, 154, 347

© in this web service Cambridge University Press www.cambridge.org

Index

portable pumps, 54
posterior subthalamic area (PSA), 218–19
postural hypotension, 42, 105
posture, 289
PPMI study, 254, 255
pramipexole, 35, 36, 37–39, 133, 156
  adverse effects, 41
  depression, 328
  early stage PD, 283–84
  formulations, 283
  major trials, 272, 275
  mechanism of action, 37
  motor symptoms efficacy, 38–39
  non-motor symptoms efficacy, 39
  pharmacokinetics, 50
PRECEPT study, 90, 273, 276
preladenant, 87
presence hallucinations, 131
PRESTO trial, 25
primary pain, 164, 165
probiotics, 99
procyclidine, 7
prodromal syndrome, 280
PROGENI study, 280
progression biomarkers, 260
proteomics, 259
PROUD study, 272, 275
prucalopride, 98, 99
psychiatric complications, dopamine agonists, 34
psychosis, 131–32, 328–29
  dopamine agonists, 42
  drug treatment causing, 132
  induction, 17
  medications causing, 131
  symptoms, 328
  treatment-related, 140–42
PSYCLOPS study, 329
psyllium, 98
punding, 66, 142
purines, 256
pyridostigmine, 96, 100

QE3 study, 273
Quality of Life (QoL), 55
  DBS and, 318
  GPi vs STN DBS, 291
  health-related scales, 236–37, 238
  PDQ-39, 84, 199
  unilateral pallidal DBS, 301
quetiapine, 132, 142, 329
QUIP-RS scale, 143, 235, 330

radicular pain, 165, 166
radiofrequency thermolesion, 178
radiotherapy, 102
ramelteon, 156
rasagiline, 68
  adverse effects, 27
  clinical trials, 26, 272, 274
  cognitive impairment, 112, 113, 327
  depression, 328
  early stage PD, 285
  EFNS/MDS guidelines, 30
  levodopa adjunct therapy, 25–26
  MDS guidelines, 30
  selegiline comparisons, 27
  sleep disturbances, 156
Rasch measurement theory, 231
rating scales, 231–32, 249
  classification, 231
  clinician-based, 232–34
  development and validation, 231
  global severity and disability, 232
  global severity and multidomain, 238
  main psychometric attributes, 232
  motor complications and dyskinesias, 233
  motor impairment and disability, 233
  motor symptoms and disabilities, 235
  multidomain, 233
  non-motor symptoms, 234, 235–36, 238
  NPS clinical trials, 332
  patient-reported outcomes, 234–36
  quality of life, 236–37, 238
RDRS scale, 234
REAL-PET study, 244, 250, 267, 272, 275
RECOVER study, 40, 51
rectal laxatives, 99
REM sleep disorder, 128, 141, 152, 153, 347
  treatment, 156
repetitive transcranial magnetic stimulation (rTMS), 104, 118, 168
reproducibility, rating scales, 232
rescue therapy, 54, 55
resistance training, 351–52
responsiveness, in rating scales, 231, 233
rest tremor, 3, 208
restless legs syndrome (RLS), 152, 156, 165, 166
restorative rehabilitation, 112, 113, 114
rigidity, 3
rivastigmine, 123, 124, 156
  apathy, 330
  cognitive impairment, 112, 113
  dementia, 325
  psychosis, 329
  sleep disorders, 347
ropinirole, 35, 36, 37, 39–40, 156
  early stage PD, 284
  major trials, 272, 275
  mechanism of action, 39
  motor systems efficacy, 39
  non-motor systems efficacy, 39
  pharmacokinetics, 50
rotigotine, 35, 36, 37, 40–41
  early stage PD, 284
  insomnia and, 155
  mechanism of action, 40
  motor systems efficacy, 40
  non-motor symptoms efficacy, 40
  pharmacokinetics, 50
rotigotine transdermal system (RTS), 49, 58
  impulse control disorders and, 52
  long-term effects, 51
  motor symptoms, 50
  non-motor symptoms, 51
  pharmacokinetics, 49–50
  side effects, 52

safinamide, 88–89, 284
SAPS-PD scores, 329
schizophrenia, 131, 142
SCOPA-AUT scale, 236
SCOPA-Cog scale, 234
SCOPA-Motor, 233
SCOPA-PC scale, 234
SCOPA-PS, 237
SCOPA-Sleep scale, 154, 236
SEAPI scale, 343
secondary pain, 164, 165
seizures, 201
selegiline, 24, 68
  adverse effects, 27
  efficacy, 24
  EFNS/MDS guidelines, 30
  insomnia from, 153
  major trials, 271, 272, 274
  MDS guidelines, 30
  neuroprotective potential, 24–25
  orally disintegrating tablet, 27
  rasagiline comparisons, 27
SEND-PD scale, 236
senna, 99
serotonin receptors, 141
serotonin syndrome, 27–28
sertraline, 328
SES scale, 233
sexual dysfunction, 104–6. *See also* erectile dysfunction
  drugs contributing to, 104
SF-36 scale, 237
shopping, compulsive, 142
sialorrhea, 8, 100–102, 337–40
  drug treatment, 95
sildenafil, 105, 343
SINDEPAR study, 272, 274
single-domain MCI, 111, 122
SIP scale, 237
skin nodules, 57
sleep attacks, 153, 157
sleep disorders, 134, 151, 346–47. *See also* REM sleep disorder
  daytime, 41, 152–53, 345–46
  diagnosis, 153
  dopamine agonists, 41
  EDS, 152, 157, 345
  guidelines, 155
  management, 154–58
  nighttime, 151–52
  pathopathology, 153
  PPN DBS and, 218
  scales, 236
smoking, 128
social phobia, 130
solanezumab, 255
solifenacin, 103
somatostatin, 282
SPECT scanning, 242, 243, 250
speech impairments, 354
speech-language therapy, 337
spinal cord, degeneration, 163
SSRIs, 130, 133, 327, 328
Stalevo®, 78, 81
standard error of measurement (SEM), 233
standardized response mean (SRM), 231
STEADY-PD study, 90

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-05386-1 — Parkinson's Disease
Edited by Néstor Gálvez-Jiménez , Hubert H. Fernandez , Alberto J. Espay , Susan H. Fox
Index
More Information

stereotactic surgery, 167, 175, 177, 198, 292, 297. *See also* deep brain stimulation (DBS)
stimulant laxatives, 99
stimulants, 135
stimulation related side effects, 201
stool softeners, 99
striatum, 5
STRIDE-PD study, 65, 68, 79
structural imaging, 243, 268
subcutaneous apomorphine, 100
subcutaneous dopamine agonists, 53–58
substantia nigra (SNr), 219–21
subthalamic nucleus (STN) DBS, 146, 147, 157, 287
  advantages, 195
  adverse effects, 198, 199–202
  anatomy and physiology, 288
  backgound, 287
  bilateral, 306–8
  future uses, 202
  vs. GPi DBS, 190, 192, 294
  indications and patient selection, 195–96
  introduction and history, 195
  mechanism of action, 199
  medication reduction, 291–92
  motor symptoms, 289–90
  neuroimaging, 292
  non-motor symptoms, 290–91
  operation risks, 293
  outcomes and efficacy, 199
  pain management, 344
  PPN DBS and, 218
  procedure, 198–99
  programming challenges following, 292
  stimulation, 288
  timing of, 196
  unilateral, 305–6
subthalamotomy, 181–82, 183, 219. *See also* surgery
  bilateral, 306
  unilateral, 304–5
suicide, 147, 201, 318
supine hypertension, 96, 97
surface electrical stimulation therapy, 341
surgery, 175, 297–98. *See also* deep brain stimulation (DBS); pallidotomy; stereotactic surgery; subthalamotomy; thalamotomy
  advantages and drawbacks, 298
  vs. DBS controversy, 308–9
  epidural spinal cord stimulation, 222–24
  indications, 176
  lesioning technique, 178
  motor cortex stimulation, 222
  non-invasive brain stimulation, 224
  outcomes, 178–82
  patient preparation, 177
  patient selection, 176
  safety and side effects, 182–83
  target confirmation, 177–78
  target planification, 177
surrogate markers, 249, 260
swallowing therapy, 340
sweating, excessive, 106
SWEDDs, 243, 266
synuclein alpha, 253–54, 268

tai-chi, 352–53
tango dancing, 355, 356
tau protein, 255, 268
TCH346 study, 273, 276
tegaserod, 98, 99, 341
TEMPO study, 26, 30, 272, 274
testosterone replacement therapy, 105
thalamic DBS, 298–300
thalamotomy, 206, 297. *See also* surgery
  introduction, 175
  non-invasive, 308
  outcomes, 178–79, 182
  vs. thalamic DBS, 298–300
thermolesion, 176, 178
thermoregulatory dysfunction, 106
tocopherol, 271, 272
tolcapone, 67, 77, 79–80
tolterodine, 102
toxin-induced models, 271
tozadenant, 87–88
transcranial direct current stimulation (tDCS), 118
transcranial ultrasound, 243
transcriptomics, 258–59
transdermal dopamine agonists, 48, 58
  apomorphine, 52
  delivery routes, 49
  lisuride, 52
  piribedil, 52
  rotigotine, 49–52
transgenic models, 271
TRAP pneumonic, 2
treadmill/gait training., 350
tremors
  anticholinergic effects, 8
  benign tremulous parkinsonism, 213
  GPi vs STN DBS, 289
  rest tremor, 208
  thalamotomy vs thalamic DBS, 299
  VIM DBS treatment, 206, 208, 210
tricyclic antidepressants, 103, 133, 327
trihexyphenidyl, 5, 7, 101
tropicamide, 101, 340
trospium, 102

Unified Dyskinesia Rating Scale, 89, 234
unilateral GPi DBS, 301–2
unilateral pallidotomy, 300–301
unilateral subthalamic DBS, 305–6
unilateral subthalamotomy, 304–5
United Kingdom Brain Bank criteria, 281
UPDRS scores, 24, 26, 67, 266, 269
  bilateral pallidal DBS, 303
  bilateral pallidotomy, 302
  bilateral STN DBS, 307
  bilateral subthalamotomy, 306
  GPi DBS, 189, 290
  MDS-UPDRS, 266
  pallidotomy, 300
  resistance training, 351
  STN DBS, 196, 199, 290
  subscales, 233
  unilateral pallidotomy, 300
  unilateral STN DBS, 305
  unilateral subthalamotomy, 305
  VIM DBS, 209
urate, 256
urge incontinence, 102
uric acid precursor, 90
urinary dysfunction, 102–4, 342–43
  drug treatment, 95
urinary incontinence, 343

validity, rating scales, 232
variability between laboratory measures, 260
venlafaxine, 133, 327
ventral intermediate nucleus (VIM) DBS, 206
  adverse effects, 211, 212
  BTP treatment, 213
  neuroanatomy, 206
  neurophysiology, 207
  procedure, 207
  rebound effect, 211
  stimulation parameters, 211
  surgery results, 208–11
verbal fluency, 317
video-assisted swallowing therapy (VAST), 340
visual analog scales (VAS), 340
visual field defects, 301
visual hallucinations, 131, 141
visuospatial deficits, 111
VitalStim®, 341
vitamin B12 deficiency, 168
vitamin D deficiency, 282
VMAT2, 267

washout period, 265, 268, 274
wearing-off, 76, 80
weight gain, 293
weight loss, 342
WINCS, 224
WOQ scale, 235

xanthine, 253
XP 21279, 69, 85–86

younger patients, treatments in early stage, 72

zona incerta (Zi), 218, 219

© in this web service Cambridge University Press www.cambridge.org